Qazi Hammad A
Department of Health and Rehab Sciences, Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada.
J Res Med Sci. 2012 Dec;17(12):1180-7.
Cystoid macular edema (CME) is a relatively common painless condition usually accompanied by blurred vision. The prevalence of CME varied from 5% to 47% depending on cause of pathology. There are several treatments available for ME including intravitreal use of bevacizumab that has been used in different doses in few studies. However, there is still scarcity of data available on the use of bevacizumab for the treatment of ME. A systematic review is needed to provide a foundational base to discuss and synthesize the available information on the effectiveness and safety of intravitreal bevacizumab in macular edema, so that recommendations and policies can be built regarding controversial use of bevacizumab in macular edema. We have planned to perform a systematic review with an objective to compare the effects of a single injection of 1.25 mg intravitreal bevacizumab (avastin) in the improvement of visual acuity, macular edema, and thickness with other interventions/controls for the treatment of macular edema at 3 and 6 months interval using randomized controlled trials. This is only a protocol of the review and we will be conducting a full length review, addressing the issue in future.
黄斑囊样水肿（CME）是一种相对常见的无痛性病症，通常伴有视力模糊。根据病理原因，CME的患病率在5%至47%之间不等。有多种治疗黄斑水肿（ME）的方法，包括玻璃体内使用贝伐单抗，在少数研究中已使用了不同剂量的贝伐单抗。然而，关于使用贝伐单抗治疗黄斑水肿的数据仍然匮乏。需要进行一项系统评价，以提供一个基础，来讨论和综合关于玻璃体内注射贝伐单抗治疗黄斑水肿有效性和安全性的现有信息，以便就贝伐单抗在黄斑水肿中的争议性使用制定建议和政策。我们计划进行一项系统评价，目的是通过随机对照试验，比较单次玻璃体内注射1.25mg贝伐单抗（阿瓦斯汀）与其他干预措施/对照在改善视力、黄斑水肿及厚度方面的效果，观察间隔时间为3个月和6个月。这只是该评价的方案，我们将在未来进行全面评价，解决这个问题。
